Cardiac Safety: Key issues and best practice for Thorough QT Studies and Intensive Phase I QT Studies

Posted:
7
November 2012

Cardiac Safety: Key issues and best practice for Thorough QT Studiesand Intensive Phase I QT Studies~ A specialist workshop sponsored by Richmond Pharmacology ~

As collaborating sponsors of the joint AMIFE IFAPP 16th International Conference on Pharmaceutical Medicine � ICPM 2012, Richmond Pharmacology welcomes attendees to join its specialist workshop on Day 2, 15 Nov exploring �Cardiac Safety: Key issues and best practice for Thorough QT Studies and Intensive Phase I QT Studies�.Co-chaired by the internationally acclaimed experts Beno�t Tyl, Georg Ferber and Jorg Taubel, the workshop will look at the biological background to the ICH E14 guidance. They will present the rationale of the thorough QT study and discuss the key elements of a state of the art design and analysis of such a study. The second half of the workshop will address the placement of the TQT study in clinical development and give an update on current CSRC discussions and on conditions under which regulators may be likely to waive a TQT study at present and in future.Attendees are encouraged to submit questions or current problems they may wish the panel to address during the roundtable discussions in advance to:info@richmondpharmacology.comView ICPM 2012 Scientific ProgramRegister for this conference

Latest news

Upcoming Event

ACCP 2020, Translating Clinical Pharmacology Research into Patient-centered Care

21 - 23 September 2020
Dr. Jorg Taubel will be presenting posters that explore the subjects of cardiac health and diabetes.
View event

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 17, 2020
Richmond Pharmacology early phase drug development update.
Read more